ADMA Biologics is trading at $11.11, up 4.03%, alongside biotech and broader-market strength; no new company announcement or clearly confirmed company-specific catalyst surfaced for October 19.
- XBI was reported up nearly 2% in early trading, while supplied market context shows major U.S. indices higher.
- An October 15 peer-reviewed IVIG manufacturing publication reported impurity removal, maintained product quality and increased yield; it does not establish the cause of Monday’s move.